Amneal Pharmaceuticals Inc. Class A Common Stock (AMRX)
Stock · NASDAQ · Health Care
$19.18as of 10/16/2026
Price chart
Active signals
AMRX Signal Track Record
How signals performed across all stocks →What AMRX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 32 | -0.2% | 50% | September 18, 2026 |
| Volume Spike | 32 | +4.2% | 66% | September 16, 2026 |
| Bollinger Band Breakdown | 11 | +5.0% | 73% | September 10, 2026 |
| 200-Day Moving Average TouchActive now | 6 | +7.1% | 67% | May 15, 2026 |
| Any 20-session window (baseline) | +4.1% | 65% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AMRX
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems,…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 8,700
- Website
- amneal.com/
Fundamentals
- 1-day range
- $19.53$20.53
- Market cap
- $5.76B
- P/E (trailing)
- 39.88
- P/E (forward)
- 16.48
- EPS (trailing)
- $0.48
- Dividend yield
- —
- Beta
- 1.22
- Avg. volume
- 2.26M
How Amneal Pharmaceuticals Inc. Class A Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
Amneal Pharmaceuticals Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- AMRXAmneal Pharmaceuticals Inc. Class A Common Stock$19.18▼ 0.36%Market cap $5.76BP/E 39.88$9.56$21.18
- MIRMMirum Pharmaceuticals Inc. Common Stock$80.14▼ 2.73%Market cap $5.74BP/E —$63.23$130
- TVTXTravere Therapeutics Inc. Common Stock$49.6▼ 6.04%Market cap $5.89BP/E —$22.59$68.73
- PTCTPTC Therapeutics Inc. Common Stock$59.24▼ 2.87%Market cap $5.91BP/E —$58.8$90.87
- KNSAKiniksa Pharmaceuticals International plc Class A Ordinary Shares$78.59▼ 1.69%Market cap $5.97BP/E 77.33$35.2$82.94
- LGNDLigand Pharmaceuticals Incorporated Common Stock$295.54▼ 0.99%Market cap $6.02BP/E 30.38$175.89$326.63
- GRFSGrifols S.A. American Depositary Shares$7.64▲ 1.33%Market cap $5.38BP/E 12.88$8.43$12.15
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AMRX Amneal Pharmaceuticals Inc. Class A Common Stock | $5.76B | 39.88 | $19.18 | ▼ 0.36% | $9.56$21.18 |
| MIRM Mirum Pharmaceuticals Inc. Common Stock | $5.74B | — | $80.14 | ▼ 2.73% | $63.23$130 |
| TVTX Travere Therapeutics Inc. Common Stock | $5.89B | — | $49.6 | ▼ 6.04% | $22.59$68.73 |
| PTCT PTC Therapeutics Inc. Common Stock | $5.91B | — | $59.24 | ▼ 2.87% | $58.8$90.87 |
| KNSA Kiniksa Pharmaceuticals International plc Class A Ordinary Shares | $5.97B | 77.33 | $78.59 | ▼ 1.69% | $35.2$82.94 |
| LGND Ligand Pharmaceuticals Incorporated Common Stock | $6.02B | 30.38 | $295.54 | ▼ 0.99% | $175.89$326.63 |
| GRFS Grifols S.A. American Depositary Shares | $5.38B | 12.88 | $7.64 | ▲ 1.33% | $8.43$12.15 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Amneal Pharmaceuticals (AMRX) Stock Gets Fair Value Bump After Analyst Backing For New LaunchesYahoo · 10/3/2026
- Oppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27Benzinga · 9/23/2026
- Amneal: Even My Bull Case Barely Justifies $20/ShareSeekingAlpha · 9/22/2026
- Why Is Amneal (AMRX) Stock Rocketing Higher TodayYahoo · 9/22/2026
- Amneal Announces FDA Approval and Launch of Lanreotide InjectionYahoo · 9/18/2026
- 3 Reasons to Avoid AMRX and 1 Stock to Buy InsteadYahoo · 9/18/2026
- Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?Yahoo · 9/17/2026
- Salesforce To Rally Around 20%? Here Are 10 Top Analyst Forecasts For ThursdayBenzinga · 9/17/2026
Insider Activity
Insider Actions →- J. Kevin Buchi · September 17, 2026 · Gift20.4K
- J. Kevin Buchi · September 11, 2026 · Option Exercise20.4K @ $14.45
- Andrew S. Boyer · September 1, 2026 · Gift80.0K
- Andrew S. Boyer · August 21, 2026 · Gift152.4K
- John Kiely · August 13, 2026 · Gift10.0K
- John Kiely · August 13, 2026 · Sale50.0K @ $17.64
- Nikita Shah · August 12, 2026 · Sale146.4K @ $17.51
- Jason B. Daly · August 12, 2026 · Sale210.0K @ $17.4
- J. Kevin Buchi · August 11, 2026 · Option Exercise168.6K @ $17.18
- Jason B. Daly · August 11, 2026 · Sale6.6K @ $17.7
- Chintu Patel · August 10, 2026 · Grant6.38M
- Gautam Patel · August 10, 2026 · Grant283.6K
- Chirag K. Patel · August 10, 2026 · Grant6.38M
- Tushar Bhikhubhai Patel · August 10, 2026 · Grant12.76M
- Deborah M. Autor · May 11, 2026 · Sale34.8K @ $12.94
Institutional Ownership
March 31, 2026
- Total shares held
- 146.11M
- Total value held
- $1.76B
- Institutional holders
- 307
- Unknown24.52M
- Unknown12.33M
- Unknown11.04M
- Unknown7.59M
- Unknown6.79M
- Unknown5.69M
- Unknown4.64M
- Unknown4.55M
- Unknown3.68M
- Unknown3.24M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
AMRX Gains Fair Value Bump After Analyst Support for New Launches
Analysts have raised AMRX's fair value after backing new product launches, lifting the stock's target range. The company is listed among low‑volatility stocks that still have open questions for investors. The move comes as the shares trade near the middle of their 52‑week range and around the 53.3 RSI level.
AMRX Gains Fair Value Bump After Analyst Support for New Launches. Analysts have raised AMRX's fair value after backing new product launches, lifting the stock's target range. The company is listed among low‑volatility stocks that still have open questions for investors. The move comes as the shares trade near the middle of their 52‑week range and around the 53.3 RSI level.